Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | PADI4 | Q9UM07 | 10/20 | 0.49 |
| ▸ | PADI2 | Q9Y2J8 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060574 | 0.92 | HDAC1 (0.66) | HDAC1MCHR1PADI4PADI2OPRM1 | |
| SCHEMBL10060140 | 0.84 | MCHR1 (0.56) | HDAC1MCHR1PADI4PADI2PADI6 | |
| SCHEMBL10060141 | 0.83 | KDM1A (0.57) | PADI4PADI2PADI6 | |
| SCHEMBL8112529 | 0.81 | HDAC1 (0.64) | HDAC1MCHR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL10060235 | 0.80 | KDM1A (0.59) | PADI4PADI2L3MBTL1PADI6 | |
| SCHEMBL13928114 | 0.80 | HDAC1 (1.00) | HDAC1MCHR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8307553 | 0.80 | HDAC1 (1.00) | HDAC1MCHR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL10060137 | 0.79 | PADI4 (0.54) | PADI4PADI2KMT2APADI6 | |
| SCHEMBL10060566 | 0.78 | PADI6 (0.69) | PADI4PADI2PADI6 | |
| SCHEMBL8128169 | 0.78 | HDAC1 (0.65) | HDAC1MCHR1PADI4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969333-B2 | Therapeutic compositions and methods | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288059-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | HDAC1 602/4885MCHR1 4874/4885PADI4 1/4885 |
| US-20120108562-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PADI4, PADI2, PADI3 | HDAC1 602/4885MCHR1 4874/4885PADI4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.